Pyrazolam

Pyrazolam is a benzodiazepine derivative originally developed by a team lead by Leo Sternbach at Hoffman-La Roche in the 1970s, and subsequently "rediscovered" and sold as a research chemical starting in 2012. It is mainly an anxiolytic, but it has also shown anticonvulsant and hypnotic effects at high doses. Pyrazolam has structural similarities to alprazolam Unlike other benzodiazepines pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine, no metabolites have been found in the urine of volunteers and has anxiolytic activity 12x stronger than diazepam while causing little ataxia and sedation when used in its anxiolytic dose range. It is most selective for the α2 and α3 receptor subtypes

Binding data (GABA):
 * α1 3.84±0.25
 * α2 1.31±0.19
 * α3 1.48±0.21
 * α5 3.72±0.32